Wall Street brokerages expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to report sales of $11.18 million for the current quarter, according to Zacks. Four analysts have issued estimates for Reata Pharmaceuticals’ earnings, with the highest sales estimate coming in at $12.60 million and the lowest estimate coming in at $7.19 million. Reata Pharmaceuticals reported sales of $12.50 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 10.6%. The business is scheduled to report its next quarterly earnings results on Friday, March 2nd.

On average, analysts expect that Reata Pharmaceuticals will report full year sales of $11.18 million for the current financial year, with estimates ranging from $45.20 million to $50.70 million. For the next fiscal year, analysts forecast that the company will post sales of $45.81 million per share, with estimates ranging from $28.20 million to $50.46 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.11). The company had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $12.54 million. The firm’s quarterly revenue was up .0% on a year-over-year basis.

A number of research firms recently weighed in on RETA. ValuEngine raised shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Zacks Investment Research raised shares of Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Cowen reissued a “buy” rating on shares of Reata Pharmaceuticals in a research report on Tuesday, November 14th. Robert W. Baird reissued a “buy” rating and issued a $47.00 price objective on shares of Reata Pharmaceuticals in a research report on Tuesday, October 24th. Finally, BidaskClub lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. Reata Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $54.71.

Reata Pharmaceuticals (NASDAQ:RETA) opened at $28.43 on Friday. The company has a debt-to-equity ratio of -0.15, a current ratio of 3.18 and a quick ratio of 3.18. Reata Pharmaceuticals has a 1-year low of $19.48 and a 1-year high of $40.88. The company has a market cap of $742.43 and a PE ratio of -19.47.

In related news, major shareholder James W. Traweek, Jr. bought 121,725 shares of Reata Pharmaceuticals stock in a transaction dated Wednesday, December 13th. The shares were acquired at an average cost of $24.88 per share, with a total value of $3,028,518.00. Following the completion of the transaction, the insider now owns 35 shares in the company, valued at approximately $870.80. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Cpmg Inc bought 200,000 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, December 14th. The shares were bought at an average cost of $24.79 per share, for a total transaction of $4,958,000.00. Following the completion of the transaction, the director now owns 113 shares of the company’s stock, valued at approximately $2,801.27. The disclosure for this purchase can be found here. Insiders purchased a total of 413,813 shares of company stock worth $10,453,354 over the last three months. 44.00% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Crestline Management LP purchased a new position in shares of Reata Pharmaceuticals during the third quarter worth approximately $1,880,000. First Allied Advisory Services Inc. purchased a new position in shares of Reata Pharmaceuticals during the third quarter worth approximately $203,000. Alyeska Investment Group L.P. purchased a new position in shares of Reata Pharmaceuticals during the third quarter worth approximately $2,832,000. California State Teachers Retirement System increased its position in shares of Reata Pharmaceuticals by 21.2% during the third quarter. California State Teachers Retirement System now owns 18,325 shares of the company’s stock worth $570,000 after acquiring an additional 3,200 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Reata Pharmaceuticals by 83.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 49,828 shares of the company’s stock worth $1,550,000 after acquiring an additional 22,628 shares during the period. 29.58% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc (RETA) Will Announce Quarterly Sales of $11.18 Million” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/14/zacks-brokerages-anticipate-reata-pharmaceuticals-inc-reta-will-announce-quarterly-sales-of-11-18-million-2.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.